Excelsus Structural Solutions AG

Excelsus offers cutting-edge, customizable, and cost-effective synchrotron-based structural characterization services for pharmaceuticals at every stage of their product lifecycle — from selection and development to manufacturing, stability studies, and IP protection. With Excelsus, you gain access to analyses via synchrotron X-ray powder diffraction characterized by exceptional angular resolution and counting statistics, enabling ultra-low levels of detection of crystalline phases in complex drug substances and drug products. Additionally, Excelsus provides innovative methodologies designed for the accurate quantification of complex polymorphic mixtures in pharmaceutical drug substances and drug products, regardless of whether valid structure models are available. Founded in 2012 as a spin-off of the renowned Paul Scherrer Institute (PSI) in Switzerland, Excelsus operates worldwide, using several synchrotron facilities, such as SLS (Switzerland), ALBA (Spain), DESY (Germany), ESRF (France), and Max IV (Sweden). Its headquarters are located at PARK INNOVAARE, a major innovation center in Switzerland, in the proximity to the PSI and its synchrotron facility. In 2023, our growing team established some laboratories on the Sankt-Johann Campus in Basel, a city which has become one of the leading biopharma hubs in Europe. Our access to state-of-the-art facilities and extensive know-how of X-ray powder diffraction enable us to detect and quantify polymorphs as low as 0.01% wt in pharmaceutical products—setting new standards for structural characterization and quality control. At Excelsus, we go beyond lab solutions, offering synchrotron services with superior performance and precision as an affordable alternative to traditional diffractometers. From structure resolution and polymorph analysis to R&D collaborations, we advance pharmaceutical characterization with unrivaled X-ray diffraction solutions. Let’s work together to bring your products to the next level!